Literature DB >> 17666480

Association between serum insulin-like growth factor-I levels and thyroid disorders in a population-based study.

Henry Völzke1, Nele Friedrich, Sabine Schipf, Robin Haring, Jan Lüdemann, Matthias Nauck, Marcus Dörr, Georg Brabant, Henri Wallaschofski.   

Abstract

OBJECTIVE: There is current debate on whether serum IGF-I levels are associated with thyroid disorders. The aims of the present study were: 1) to investigate possible associations between serum IGF-I levels and thyroid disorders and 2) to analyze the role of serum IGF binding protein (IGFBP)-3 and TSH levels for these associations.
DESIGN: This was a cross-sectional Study of Health in Pomerania.
SETTING: The study was conducted in the general population of northeast Germany.
SUBJECTS: The study population comprised 3662 subjects (1746 women) without history of thyroid disorders.
INTERVENTIONS: No interventions have been performed. MAIN OUTCOME MEASURES: Goiter and thyroid nodules were determined by ultrasound. Serum TSH levels less than 0.25 mIU/liter were considered decreased.
RESULTS: Adjusted for major confounders and risk factors for thyroid disorders, subjects with serum IGF-I levels above the upper tertile had higher odds for goiter relative to subjects with serum IGF-I levels below the lower tertile [odds ratio (OR) 1.67; 95% confidence interval (CI) 1.24-2.26 in women; OR 2.04; 95% CI 1.55-2.68 in men]. A similar association was present for thyroid nodules in men (OR 1.64; 95% CI 1.17-2.32) and for decreased serum TSH levels in women (OR 1.65; 95% CI 1.00-2.69). Serum IGFBP-3 levels were not associated with thyroid disorders and did not represent effect modifiers for the association between serum IGF-I levels and the endpoints.
CONCLUSIONS: We conclude that high serum IGF-I levels are associated with goiter. Whereas high serum IGF-I levels are also related to thyroid nodules in men, they are related to decreased serum TSH levels in women. Serum IGFBP-3 and TSH levels did not modulate these associations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17666480     DOI: 10.1210/jc.2007-0816

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

1.  TSH compensates thyroid-specific IGF-I receptor knockout and causes papillary thyroid hyperplasia.

Authors:  Kathrin Müller; Dagmar Führer; Jens Mittag; Nora Klöting; Matthias Blüher; Roy E Weiss; Marie-Christine Many; Kurt Werner Schmid; Knut Krohn
Journal:  Mol Endocrinol       Date:  2011-10-06

2.  Is there a Relationship between Serum IGF-1 and Thyroid Nodule, Thyroid or Ovarian Volume in Polycystic Ovarian Syndrome?

Authors:  O Topaloglu; B Evren; M Uzun; S Yologlu; E Guldogan; I Sahin
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

3.  Association of insulin-like growth factor-1 with thyroid nodules.

Authors:  Ying-Jian Liu; Wei Qiang; Xing-Jun Liu; Li Xu; Hui Guo; Li-Ping Wu; Bingyin Shi
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

4.  Thyroid fine needle aspiration biopsies in children: study of cytological-histological correlation and immunostaining with thyroid peroxidase monoclonal antibodies.

Authors:  Victoria Hoperia; Alexander Larin; Kirk Jensen; Andrew Bauer; Vasily Vasko
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-21

5.  The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds.

Authors:  Robert Udelsman; Yawei Zhang
Journal:  Thyroid       Date:  2013-10-29       Impact factor: 6.568

6.  The role of insulin-like growth factor 1 in the development of benign and malignant thyroid nodules.

Authors:  Engin Baştürk; Metin Kement; Dilek Yavuzer; Selahattin Vural; Cem Gezen; Hülya Ilıksu Gözü; Ayşe Karadayı; Mustafa Oncel
Journal:  Balkan Med J       Date:  2012-06-01       Impact factor: 2.021

Review 7.  IGF Bioregulation System in Benign and Malignant Thyroid Nodular Disease: A Systematic Review.

Authors:  Apostolos Karagiannis; Eva Kassi; Antonios Chatzigeorgiou; Michael Koutsilieris
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

8.  Diosgenin relieves goiter via the inhibition of thyrocyte proliferation in a mouse model of Graves' disease.

Authors:  Hu Cai; Zhe Wang; Hai-qing Zhang; Fu-rong Wang; Chun-xiao Yu; Feng-xia Zhang; Ling Gao; Jian Zhang; Jia-jun Zhao
Journal:  Acta Pharmacol Sin       Date:  2013-11-18       Impact factor: 6.150

9.  Conditional deletion of insulin receptor in thyrocytes does not affect thyroid structure and function.

Authors:  Sangmi Ock; Seok Hong Lee; Jihyun Ahn; Tae Jin Lee; Chung-Hyun Cho; E Dale Abel; Shioko Kimura; Jaetaek Kim
Journal:  Endocr J       Date:  2011-09-08       Impact factor: 2.349

10.  Insulin-like growth factor-i and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition.

Authors:  Julie A Schmidt; Naomi E Allen; Martin Almquist; Silvia Franceschi; Sabina Rinaldi; Sarah J Tipper; Konstantinos K Tsilidis; Elisabete Weiderpass; Kim Overvad; Anne Tjønneland; Marie-Christine Boutron-Ruault; Laure Dossus; Sylvie Mesrine; Rudolf Kaaks; Annekatrin Lukanova; Heiner Boeing; Pagona Lagiou; Dimitrios Trichopoulos; Antonia Trichopoulou; Domenico Palli; Vittorio Krogh; Salvatore Panico; Rosario Tumino; Roberto Zanetti; H Bas Bueno-de-Mesquita; Petra H Peeters; Eiliv Lund; Virginia Menéndez; Antonio Agudo; María-José Sánchez; Maria-Dolores Chirlaque; Eva Ardanaz; Nerea Larrañaga; Joakim Hennings; Maria Sandström; Kay-Tee Khaw; Nick Wareham; Isabelle Romieu; Marc J Gunter; Elio Riboli; Timothy J Key; Ruth C Travis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-19       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.